Spravato, a depression treatment derived from club drug ketamine, was looking like a dud. Its recent success now shows a path forward for psychedelic-based medicines.
Related Posts
Auto & Transport Roundup: Market Talk
Lufthansa, Allegiant Air and more in the latest Market Talks covering the Auto and Transport sector.
Commerzbank Confirms Independent Strategy Ahead of Talks With UniCredit
The German lender said it planned to improve its profitability and boost shareholder returns as it grapples with a possible takeover attempt by Italy’s UniCredit.
Mitsubishi Corp. in Talks to Buy Stake in Exxon Mobil’s Texas Project
Mitsubishi Corp. is in talks to buy a stake in Exxon Mobil’s project in Baytown, Texas, which aims to be the world’s largest low-carbon ammonia […]